Proportion of people with serious adverse events · acute exacerbations of chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of people with serious adverse events · acute exacerbations of chronic obstructive pulmonary disease
1 finding from 1 review
Adverse effect/event(s) ‐ serious adverse events · schizophrenia or related disorders
It is very uncertain whether modafinil changes adverse effect/event(s) ‐ serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
Serious adverse events Duration 3 days to 3 weeks · acute asthma exacerbation
Antibiotics showed no clear difference in serious adverse events Duration 3 days to 3 weeks compared with placebo or usual care (low certainty).
1 finding from 1 review
Non‐serious adverse events assessed using ICH‐GCP
It is very uncertain whether L‐ornithine L aspartate changes non‐serious adverse events assessed using ICH‐GCP compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Serious adverse events (dichotomous data) ‐ shock · critically ill patients
Corticosteroids showed no clear difference in serious adverse events (dichotomous data) ‐ shock compared with placebo compared (high certainty).
1 finding from 1 review
Incidence of serious adverse events ‐ not reported · adults with alopecia areata
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Participants with 1 or more serious adverse events · patients with Guillain‐Barré syndrome
It is very uncertain whether brain‐derived neurotrophic factor changes participants with 1 or more serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
Participants with 1 or more serious adverse events · adults with severe Guillain‐Barré syndrome (GBS disability score > 2), within 2 weeks form onset
Eculizumab showed no clear difference in participants with 1 or more serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Participants with 1 or more serious adverse events · patients with Guillain‐Barré syndrome
It is very uncertain whether interferon beta‐1a changes participants with 1 or more serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
Participants experiencing anyserious adverseevents · adults with chronic neuropathic pain
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Proportion of infants with serious adverse events ( · HIV‐positive pregnant women co‐infected with hepatitis B virus
It is very uncertain whether tenofovir‐based antiviral combination regimens changes proportion of infants with serious adverse events ( compared with placebo or tenofovir alone or non‐tenofovir‐based antiviral regimens (very low certainty).
1 finding from 1 review
Proportion of mothers with serious adverse events ( · HIV‐positive pregnant women co‐infected with hepatitis B virus
It is very uncertain whether tenofovir‐based antiviral combination regimens changes proportion of mothers with serious adverse events ( compared with placebo or tenofovir alone or non‐tenofovir‐based antiviral regimens (very low certainty).
1 finding from 1 review
Total number of serious adverse events not measured · patients with osteoarthritis
The review found no eligible studies for this question.
1 finding from 1 review
Participants with one or more serious adverse events · people with active systemic lupus erythematosus (but not active nephritis or active central nervous system involvement)
Belimumab 10 mg/kg showed no clear difference in participants with one or more serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events (excluding death) at 24 weeks · vascular dementia and other vascular cognitive impairments
Donepezil 10 mg showed no clear difference in serious adverse events (excluding death) at 24 weeks compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events (excluding death) at 24 weeks · vascular dementia and other vascular cognitive impairments
Donepezil 5 mg showed no clear difference in serious adverse events (excluding death) at 24 weeks compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events or complications of treatment
1 finding from 1 review
Serious adverse events ‐ total number of participants · prevention and treatment of hepatic encephalopathy in people with cirrhosis
Summary of findings table ‐ Rifaximin showed no clear difference in serious adverse events ‐ total number of participants compared with placebo/no intervention (moderate certainty).
1 finding from 1 review
Serious adverse events (excluding deaths) at 26 weeks · vascular dementia and other vascular cognitive impairments
Galantamine showed no clear difference in serious adverse events (excluding deaths) at 26 weeks compared with placebo (moderate certainty).
1 finding from 1 review